Factors Affecting the Outcome of Related Allogeneic Hematopoietic Cell Transplantation in Patients with Fanconi Anemia

Abstract Hematopoietic cell transplantation (HCT) can cure bone marrow failure in patients with Fanconi Anemia (FA), and it is generally accepted that these patients should receive low-intensity conditioning because of the underlying DNA repair defect in their cells. Outcomes for recipients of match...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biology of blood and marrow transplantation 2014-10, Vol.20 (10), p.1599-1603
Hauptverfasser: Ayas, Mouhab, Siddiqui, Khawar, Al-Jefri, Abdullah, El-Solh, Hassan, Al-Ahmari, Ali, Khairy, Ashraf, Markiz, Samer, Shahin, Hasan, Al-Musa, Abdulrahman, Al-Seraihy, Amal
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1603
container_issue 10
container_start_page 1599
container_title Biology of blood and marrow transplantation
container_volume 20
creator Ayas, Mouhab
Siddiqui, Khawar
Al-Jefri, Abdullah
El-Solh, Hassan
Al-Ahmari, Ali
Khairy, Ashraf
Markiz, Samer
Shahin, Hasan
Al-Musa, Abdulrahman
Al-Seraihy, Amal
description Abstract Hematopoietic cell transplantation (HCT) can cure bone marrow failure in patients with Fanconi Anemia (FA), and it is generally accepted that these patients should receive low-intensity conditioning because of the underlying DNA repair defect in their cells. Outcomes for recipients of matched related HCT have generally been favorable, but only a few studies have scrutinized the factors that may affect the eventual outcome of these patients. This retrospective analysis of 94 pediatric patients with FA who underwent related HCT at King Faisal Specialist Hospital & Research Center was carried out to attempt to identify factors that may affect outcome. Results showed overall survival (OS) probabilities of 92.5%, 89%, and 86% at 1, 5, and 10 years, respectively. In univariate analysis, use of higher dose cyclophosphamide (CY) (60 mg/kg) conditioning was associated with a better 10-year OS than lower dose CY (20 mg/kg) conditioning (91% versus 82%, respectively; P  = .035), and use of radiation-containing regimens was associated with a significantly lower 10-year OS than nonradiation regimens (76% versus 91%, respectively; P  = .005). Of the 4 regimens used in this study, the fludarabine-based regimen was associated with the highest survival (95.2%; P  = .034). The use of the higher dose CY (60 mg/kg) was associated with a significantly increased incidence of hemorrhagic cystitis (HC) (20% versus 5.6% respectively; P  = .049). Three patients (3%) developed squamous cell carcinoma (2 oropharyngeal and 1 genitourinary), at 9.4, 5.4, and 13.3 years after HCT; 2 of them had radiation-containing conditioning. In conclusion, our data suggest that although using a higher dose CY (60 mg/kg) conditioning regimen may be associated with better survival, it is also associated with a significantly increased risk of HC. The addition of fludarabine to the low-dose CY (20 mg/kg) is associated with the best survival. On the other hand, radiation-containing regimens are associated with significantly lower survival.
doi_str_mv 10.1016/j.bbmt.2014.06.016
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1561971028</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1083879114003668</els_id><sourcerecordid>1561971028</sourcerecordid><originalsourceid>FETCH-LOGICAL-c488t-432b1ac9b42e98a95ec2d252eb482ab8f156eb7ac039f0a007aa49a57739bbdc3</originalsourceid><addsrcrecordid>eNp9kUFv1DAQhSMEoqXwBzggH7kk2E7i2BJCWq1YilSpCMrZGjuT1ktiL7ZT1H-PV1s4cODk8ei9p5lvquo1ow2jTLzbN8YsueGUdQ0VTWk9qc5Zz9ta9K14Wmoq21oOip1VL1LaU0qHTqrn1RnvlKCCy_Pqfgc2h5jIZprQZudvSb5Dcr1mGxYkYSJfcYaMI9nMc7hFj86SS1wgh0NwmMtvi_NMbiL4dJjBZ8gueOI8-VIq9DmRXy7fkR14G7wjG4-Lg5fVswnmhK8e34vq--7jzfayvrr-9Hm7uaptJ2Wuu5YbBlaZjqOSoHq0fOQ9R9NJDkZOrBdoBrC0VROFsh9Ap6AfhlYZM9r2onp7yj3E8HPFlPXiki0Dg8ewJl38TA2Mclmk_CS1MaQUcdKH6BaID5pRfeSt9_rIWx95ayp0aRXTm8f81Sw4_rX8AVwE708CLFveO4w62ULF4uhi4a3H4P6f_-Efu52ddxbmH_iAaR_W6As_zXTimupvx4sfD846SlshZPsb4-Cnyw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1561971028</pqid></control><display><type>article</type><title>Factors Affecting the Outcome of Related Allogeneic Hematopoietic Cell Transplantation in Patients with Fanconi Anemia</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Ayas, Mouhab ; Siddiqui, Khawar ; Al-Jefri, Abdullah ; El-Solh, Hassan ; Al-Ahmari, Ali ; Khairy, Ashraf ; Markiz, Samer ; Shahin, Hasan ; Al-Musa, Abdulrahman ; Al-Seraihy, Amal</creator><creatorcontrib>Ayas, Mouhab ; Siddiqui, Khawar ; Al-Jefri, Abdullah ; El-Solh, Hassan ; Al-Ahmari, Ali ; Khairy, Ashraf ; Markiz, Samer ; Shahin, Hasan ; Al-Musa, Abdulrahman ; Al-Seraihy, Amal</creatorcontrib><description>Abstract Hematopoietic cell transplantation (HCT) can cure bone marrow failure in patients with Fanconi Anemia (FA), and it is generally accepted that these patients should receive low-intensity conditioning because of the underlying DNA repair defect in their cells. Outcomes for recipients of matched related HCT have generally been favorable, but only a few studies have scrutinized the factors that may affect the eventual outcome of these patients. This retrospective analysis of 94 pediatric patients with FA who underwent related HCT at King Faisal Specialist Hospital &amp; Research Center was carried out to attempt to identify factors that may affect outcome. Results showed overall survival (OS) probabilities of 92.5%, 89%, and 86% at 1, 5, and 10 years, respectively. In univariate analysis, use of higher dose cyclophosphamide (CY) (60 mg/kg) conditioning was associated with a better 10-year OS than lower dose CY (20 mg/kg) conditioning (91% versus 82%, respectively; P  = .035), and use of radiation-containing regimens was associated with a significantly lower 10-year OS than nonradiation regimens (76% versus 91%, respectively; P  = .005). Of the 4 regimens used in this study, the fludarabine-based regimen was associated with the highest survival (95.2%; P  = .034). The use of the higher dose CY (60 mg/kg) was associated with a significantly increased incidence of hemorrhagic cystitis (HC) (20% versus 5.6% respectively; P  = .049). Three patients (3%) developed squamous cell carcinoma (2 oropharyngeal and 1 genitourinary), at 9.4, 5.4, and 13.3 years after HCT; 2 of them had radiation-containing conditioning. In conclusion, our data suggest that although using a higher dose CY (60 mg/kg) conditioning regimen may be associated with better survival, it is also associated with a significantly increased risk of HC. The addition of fludarabine to the low-dose CY (20 mg/kg) is associated with the best survival. On the other hand, radiation-containing regimens are associated with significantly lower survival.</description><identifier>ISSN: 1083-8791</identifier><identifier>EISSN: 1523-6536</identifier><identifier>DOI: 10.1016/j.bbmt.2014.06.016</identifier><identifier>PMID: 24960628</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adolescent ; Carcinoma, Squamous Cell - chemically induced ; Carcinoma, Squamous Cell - immunology ; Carcinoma, Squamous Cell - mortality ; Carcinoma, Squamous Cell - pathology ; Child ; Child, Preschool ; Cyclophosphamide ; Cyclophosphamide - adverse effects ; Cystitis - chemically induced ; Cystitis - immunology ; Cystitis - mortality ; Cystitis - pathology ; Fanconi anemia ; Fanconi Anemia - immunology ; Fanconi Anemia - mortality ; Fanconi Anemia - pathology ; Fanconi Anemia - therapy ; Female ; Gamma Rays - adverse effects ; Hematology, Oncology and Palliative Medicine ; Hematopoietic Stem Cell Transplantation ; Hemorrhage - chemically induced ; Hemorrhage - immunology ; Hemorrhage - mortality ; Hemorrhage - pathology ; Histocompatibility Testing ; Humans ; Infant ; Male ; Myeloablative Agonists - adverse effects ; Oropharyngeal Neoplasms - chemically induced ; Oropharyngeal Neoplasms - immunology ; Oropharyngeal Neoplasms - mortality ; Oropharyngeal Neoplasms - pathology ; Radiation ; Retrospective Studies ; Siblings ; Stem cell transplantation ; Survival Analysis ; Transplantation Conditioning - methods ; Transplantation, Homologous ; Unrelated Donors ; Vidarabine - adverse effects ; Vidarabine - analogs &amp; derivatives</subject><ispartof>Biology of blood and marrow transplantation, 2014-10, Vol.20 (10), p.1599-1603</ispartof><rights>American Society for Blood and Marrow Transplantation</rights><rights>2014 American Society for Blood and Marrow Transplantation</rights><rights>Copyright © 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c488t-432b1ac9b42e98a95ec2d252eb482ab8f156eb7ac039f0a007aa49a57739bbdc3</citedby><cites>FETCH-LOGICAL-c488t-432b1ac9b42e98a95ec2d252eb482ab8f156eb7ac039f0a007aa49a57739bbdc3</cites><orcidid>0000-0002-8732-5611</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.bbmt.2014.06.016$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,45994</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24960628$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ayas, Mouhab</creatorcontrib><creatorcontrib>Siddiqui, Khawar</creatorcontrib><creatorcontrib>Al-Jefri, Abdullah</creatorcontrib><creatorcontrib>El-Solh, Hassan</creatorcontrib><creatorcontrib>Al-Ahmari, Ali</creatorcontrib><creatorcontrib>Khairy, Ashraf</creatorcontrib><creatorcontrib>Markiz, Samer</creatorcontrib><creatorcontrib>Shahin, Hasan</creatorcontrib><creatorcontrib>Al-Musa, Abdulrahman</creatorcontrib><creatorcontrib>Al-Seraihy, Amal</creatorcontrib><title>Factors Affecting the Outcome of Related Allogeneic Hematopoietic Cell Transplantation in Patients with Fanconi Anemia</title><title>Biology of blood and marrow transplantation</title><addtitle>Biol Blood Marrow Transplant</addtitle><description>Abstract Hematopoietic cell transplantation (HCT) can cure bone marrow failure in patients with Fanconi Anemia (FA), and it is generally accepted that these patients should receive low-intensity conditioning because of the underlying DNA repair defect in their cells. Outcomes for recipients of matched related HCT have generally been favorable, but only a few studies have scrutinized the factors that may affect the eventual outcome of these patients. This retrospective analysis of 94 pediatric patients with FA who underwent related HCT at King Faisal Specialist Hospital &amp; Research Center was carried out to attempt to identify factors that may affect outcome. Results showed overall survival (OS) probabilities of 92.5%, 89%, and 86% at 1, 5, and 10 years, respectively. In univariate analysis, use of higher dose cyclophosphamide (CY) (60 mg/kg) conditioning was associated with a better 10-year OS than lower dose CY (20 mg/kg) conditioning (91% versus 82%, respectively; P  = .035), and use of radiation-containing regimens was associated with a significantly lower 10-year OS than nonradiation regimens (76% versus 91%, respectively; P  = .005). Of the 4 regimens used in this study, the fludarabine-based regimen was associated with the highest survival (95.2%; P  = .034). The use of the higher dose CY (60 mg/kg) was associated with a significantly increased incidence of hemorrhagic cystitis (HC) (20% versus 5.6% respectively; P  = .049). Three patients (3%) developed squamous cell carcinoma (2 oropharyngeal and 1 genitourinary), at 9.4, 5.4, and 13.3 years after HCT; 2 of them had radiation-containing conditioning. In conclusion, our data suggest that although using a higher dose CY (60 mg/kg) conditioning regimen may be associated with better survival, it is also associated with a significantly increased risk of HC. The addition of fludarabine to the low-dose CY (20 mg/kg) is associated with the best survival. On the other hand, radiation-containing regimens are associated with significantly lower survival.</description><subject>Adolescent</subject><subject>Carcinoma, Squamous Cell - chemically induced</subject><subject>Carcinoma, Squamous Cell - immunology</subject><subject>Carcinoma, Squamous Cell - mortality</subject><subject>Carcinoma, Squamous Cell - pathology</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Cyclophosphamide</subject><subject>Cyclophosphamide - adverse effects</subject><subject>Cystitis - chemically induced</subject><subject>Cystitis - immunology</subject><subject>Cystitis - mortality</subject><subject>Cystitis - pathology</subject><subject>Fanconi anemia</subject><subject>Fanconi Anemia - immunology</subject><subject>Fanconi Anemia - mortality</subject><subject>Fanconi Anemia - pathology</subject><subject>Fanconi Anemia - therapy</subject><subject>Female</subject><subject>Gamma Rays - adverse effects</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Hemorrhage - chemically induced</subject><subject>Hemorrhage - immunology</subject><subject>Hemorrhage - mortality</subject><subject>Hemorrhage - pathology</subject><subject>Histocompatibility Testing</subject><subject>Humans</subject><subject>Infant</subject><subject>Male</subject><subject>Myeloablative Agonists - adverse effects</subject><subject>Oropharyngeal Neoplasms - chemically induced</subject><subject>Oropharyngeal Neoplasms - immunology</subject><subject>Oropharyngeal Neoplasms - mortality</subject><subject>Oropharyngeal Neoplasms - pathology</subject><subject>Radiation</subject><subject>Retrospective Studies</subject><subject>Siblings</subject><subject>Stem cell transplantation</subject><subject>Survival Analysis</subject><subject>Transplantation Conditioning - methods</subject><subject>Transplantation, Homologous</subject><subject>Unrelated Donors</subject><subject>Vidarabine - adverse effects</subject><subject>Vidarabine - analogs &amp; derivatives</subject><issn>1083-8791</issn><issn>1523-6536</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kUFv1DAQhSMEoqXwBzggH7kk2E7i2BJCWq1YilSpCMrZGjuT1ktiL7ZT1H-PV1s4cODk8ei9p5lvquo1ow2jTLzbN8YsueGUdQ0VTWk9qc5Zz9ta9K14Wmoq21oOip1VL1LaU0qHTqrn1RnvlKCCy_Pqfgc2h5jIZprQZudvSb5Dcr1mGxYkYSJfcYaMI9nMc7hFj86SS1wgh0NwmMtvi_NMbiL4dJjBZ8gueOI8-VIq9DmRXy7fkR14G7wjG4-Lg5fVswnmhK8e34vq--7jzfayvrr-9Hm7uaptJ2Wuu5YbBlaZjqOSoHq0fOQ9R9NJDkZOrBdoBrC0VROFsh9Ap6AfhlYZM9r2onp7yj3E8HPFlPXiki0Dg8ewJl38TA2Mclmk_CS1MaQUcdKH6BaID5pRfeSt9_rIWx95ayp0aRXTm8f81Sw4_rX8AVwE708CLFveO4w62ULF4uhi4a3H4P6f_-Efu52ddxbmH_iAaR_W6As_zXTimupvx4sfD846SlshZPsb4-Cnyw</recordid><startdate>20141001</startdate><enddate>20141001</enddate><creator>Ayas, Mouhab</creator><creator>Siddiqui, Khawar</creator><creator>Al-Jefri, Abdullah</creator><creator>El-Solh, Hassan</creator><creator>Al-Ahmari, Ali</creator><creator>Khairy, Ashraf</creator><creator>Markiz, Samer</creator><creator>Shahin, Hasan</creator><creator>Al-Musa, Abdulrahman</creator><creator>Al-Seraihy, Amal</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-8732-5611</orcidid></search><sort><creationdate>20141001</creationdate><title>Factors Affecting the Outcome of Related Allogeneic Hematopoietic Cell Transplantation in Patients with Fanconi Anemia</title><author>Ayas, Mouhab ; Siddiqui, Khawar ; Al-Jefri, Abdullah ; El-Solh, Hassan ; Al-Ahmari, Ali ; Khairy, Ashraf ; Markiz, Samer ; Shahin, Hasan ; Al-Musa, Abdulrahman ; Al-Seraihy, Amal</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c488t-432b1ac9b42e98a95ec2d252eb482ab8f156eb7ac039f0a007aa49a57739bbdc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adolescent</topic><topic>Carcinoma, Squamous Cell - chemically induced</topic><topic>Carcinoma, Squamous Cell - immunology</topic><topic>Carcinoma, Squamous Cell - mortality</topic><topic>Carcinoma, Squamous Cell - pathology</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Cyclophosphamide</topic><topic>Cyclophosphamide - adverse effects</topic><topic>Cystitis - chemically induced</topic><topic>Cystitis - immunology</topic><topic>Cystitis - mortality</topic><topic>Cystitis - pathology</topic><topic>Fanconi anemia</topic><topic>Fanconi Anemia - immunology</topic><topic>Fanconi Anemia - mortality</topic><topic>Fanconi Anemia - pathology</topic><topic>Fanconi Anemia - therapy</topic><topic>Female</topic><topic>Gamma Rays - adverse effects</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Hemorrhage - chemically induced</topic><topic>Hemorrhage - immunology</topic><topic>Hemorrhage - mortality</topic><topic>Hemorrhage - pathology</topic><topic>Histocompatibility Testing</topic><topic>Humans</topic><topic>Infant</topic><topic>Male</topic><topic>Myeloablative Agonists - adverse effects</topic><topic>Oropharyngeal Neoplasms - chemically induced</topic><topic>Oropharyngeal Neoplasms - immunology</topic><topic>Oropharyngeal Neoplasms - mortality</topic><topic>Oropharyngeal Neoplasms - pathology</topic><topic>Radiation</topic><topic>Retrospective Studies</topic><topic>Siblings</topic><topic>Stem cell transplantation</topic><topic>Survival Analysis</topic><topic>Transplantation Conditioning - methods</topic><topic>Transplantation, Homologous</topic><topic>Unrelated Donors</topic><topic>Vidarabine - adverse effects</topic><topic>Vidarabine - analogs &amp; derivatives</topic><toplevel>online_resources</toplevel><creatorcontrib>Ayas, Mouhab</creatorcontrib><creatorcontrib>Siddiqui, Khawar</creatorcontrib><creatorcontrib>Al-Jefri, Abdullah</creatorcontrib><creatorcontrib>El-Solh, Hassan</creatorcontrib><creatorcontrib>Al-Ahmari, Ali</creatorcontrib><creatorcontrib>Khairy, Ashraf</creatorcontrib><creatorcontrib>Markiz, Samer</creatorcontrib><creatorcontrib>Shahin, Hasan</creatorcontrib><creatorcontrib>Al-Musa, Abdulrahman</creatorcontrib><creatorcontrib>Al-Seraihy, Amal</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biology of blood and marrow transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ayas, Mouhab</au><au>Siddiqui, Khawar</au><au>Al-Jefri, Abdullah</au><au>El-Solh, Hassan</au><au>Al-Ahmari, Ali</au><au>Khairy, Ashraf</au><au>Markiz, Samer</au><au>Shahin, Hasan</au><au>Al-Musa, Abdulrahman</au><au>Al-Seraihy, Amal</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Factors Affecting the Outcome of Related Allogeneic Hematopoietic Cell Transplantation in Patients with Fanconi Anemia</atitle><jtitle>Biology of blood and marrow transplantation</jtitle><addtitle>Biol Blood Marrow Transplant</addtitle><date>2014-10-01</date><risdate>2014</risdate><volume>20</volume><issue>10</issue><spage>1599</spage><epage>1603</epage><pages>1599-1603</pages><issn>1083-8791</issn><eissn>1523-6536</eissn><abstract>Abstract Hematopoietic cell transplantation (HCT) can cure bone marrow failure in patients with Fanconi Anemia (FA), and it is generally accepted that these patients should receive low-intensity conditioning because of the underlying DNA repair defect in their cells. Outcomes for recipients of matched related HCT have generally been favorable, but only a few studies have scrutinized the factors that may affect the eventual outcome of these patients. This retrospective analysis of 94 pediatric patients with FA who underwent related HCT at King Faisal Specialist Hospital &amp; Research Center was carried out to attempt to identify factors that may affect outcome. Results showed overall survival (OS) probabilities of 92.5%, 89%, and 86% at 1, 5, and 10 years, respectively. In univariate analysis, use of higher dose cyclophosphamide (CY) (60 mg/kg) conditioning was associated with a better 10-year OS than lower dose CY (20 mg/kg) conditioning (91% versus 82%, respectively; P  = .035), and use of radiation-containing regimens was associated with a significantly lower 10-year OS than nonradiation regimens (76% versus 91%, respectively; P  = .005). Of the 4 regimens used in this study, the fludarabine-based regimen was associated with the highest survival (95.2%; P  = .034). The use of the higher dose CY (60 mg/kg) was associated with a significantly increased incidence of hemorrhagic cystitis (HC) (20% versus 5.6% respectively; P  = .049). Three patients (3%) developed squamous cell carcinoma (2 oropharyngeal and 1 genitourinary), at 9.4, 5.4, and 13.3 years after HCT; 2 of them had radiation-containing conditioning. In conclusion, our data suggest that although using a higher dose CY (60 mg/kg) conditioning regimen may be associated with better survival, it is also associated with a significantly increased risk of HC. The addition of fludarabine to the low-dose CY (20 mg/kg) is associated with the best survival. On the other hand, radiation-containing regimens are associated with significantly lower survival.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>24960628</pmid><doi>10.1016/j.bbmt.2014.06.016</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0002-8732-5611</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1083-8791
ispartof Biology of blood and marrow transplantation, 2014-10, Vol.20 (10), p.1599-1603
issn 1083-8791
1523-6536
language eng
recordid cdi_proquest_miscellaneous_1561971028
source MEDLINE; ScienceDirect Journals (5 years ago - present); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects Adolescent
Carcinoma, Squamous Cell - chemically induced
Carcinoma, Squamous Cell - immunology
Carcinoma, Squamous Cell - mortality
Carcinoma, Squamous Cell - pathology
Child
Child, Preschool
Cyclophosphamide
Cyclophosphamide - adverse effects
Cystitis - chemically induced
Cystitis - immunology
Cystitis - mortality
Cystitis - pathology
Fanconi anemia
Fanconi Anemia - immunology
Fanconi Anemia - mortality
Fanconi Anemia - pathology
Fanconi Anemia - therapy
Female
Gamma Rays - adverse effects
Hematology, Oncology and Palliative Medicine
Hematopoietic Stem Cell Transplantation
Hemorrhage - chemically induced
Hemorrhage - immunology
Hemorrhage - mortality
Hemorrhage - pathology
Histocompatibility Testing
Humans
Infant
Male
Myeloablative Agonists - adverse effects
Oropharyngeal Neoplasms - chemically induced
Oropharyngeal Neoplasms - immunology
Oropharyngeal Neoplasms - mortality
Oropharyngeal Neoplasms - pathology
Radiation
Retrospective Studies
Siblings
Stem cell transplantation
Survival Analysis
Transplantation Conditioning - methods
Transplantation, Homologous
Unrelated Donors
Vidarabine - adverse effects
Vidarabine - analogs & derivatives
title Factors Affecting the Outcome of Related Allogeneic Hematopoietic Cell Transplantation in Patients with Fanconi Anemia
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T19%3A43%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Factors%20Affecting%20the%20Outcome%20of%20Related%20Allogeneic%20Hematopoietic%20Cell%20Transplantation%20in%20Patients%20with%20Fanconi%20Anemia&rft.jtitle=Biology%20of%20blood%20and%20marrow%20transplantation&rft.au=Ayas,%20Mouhab&rft.date=2014-10-01&rft.volume=20&rft.issue=10&rft.spage=1599&rft.epage=1603&rft.pages=1599-1603&rft.issn=1083-8791&rft.eissn=1523-6536&rft_id=info:doi/10.1016/j.bbmt.2014.06.016&rft_dat=%3Cproquest_cross%3E1561971028%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1561971028&rft_id=info:pmid/24960628&rft_els_id=S1083879114003668&rfr_iscdi=true